Shire Says Investors More Favorable Now To Baxalta Bid
This article was originally published in Scrip
Executive Summary
Shire PLC's large investors are more on board with the firm's pursuit of Baxalta Inc. than they were when the bid first was announced in August, and the specialty pharma says it will continue to seek a merger that would create a rare disease powerhouse with 30 new products and $20bn in annual revenue by 2020.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian
Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.